It can not only enhance the cytotoxic activity of immune cells by blocking PD1/PDL1 axis, but also reduce immune escape via Pbrm1/PDL1 gene silencing, leading to a significant improvement in tumor immuno‐gene therapy. The gene discussed is PBRM1; the disease is neoplasm.